Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma

No established standard of care exists for relapsed/refractory (RR) follicular lymphoma (FL) after ≥2 prior therapies. We conducted indirect treatment comparisons (ITCs) to compare the efficacy and tolerability of mosunetuzumab with those of available treatments used in this setting.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 28, 2023 Category: Hematology Authors: Francesc Bosch, John Kuruvilla, Theodoros P. Vassilakopoulos, Danilo Di Maio, Michael C. Wei, Marie-Helene Blanchet Zumofen, Loretta J. Nastoupil Tags: Original Study Source Type: research